{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:28:11Z","timestamp":1786980491885,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10067-025-07465-1","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T06:04:37Z","timestamp":1746684277000},"page":"2087-2093","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tofacitinib as a possible treatment in macrophage activation syndrome: a pilot single-center study in China"],"prefix":"10.1007","volume":"44","author":[{"given":"Weilin","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8570-1451","authenticated-orcid":false,"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"issue":"12","key":"7465_CR1","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1007\/s10067-018-4095-1","volume":"37","author":"HE S\u00f6nmez","year":"2018","unstructured":"S\u00f6nmez HE, Demir S, Bilginer Y, \u00f6zen S, (2018) Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clin Rheumatol 37(12):3329\u20133335. https:\/\/doi.org\/10.1007\/s10067-018-4095-1","journal-title":"Clin Rheumatol"},{"issue":"5","key":"7465_CR2","doi-asserted-by":"publisher","first-page":"e267715","DOI":"10.1371\/journal.pone.0267715","volume":"17","author":"SH Nam","year":"2022","unstructured":"Nam SH, Ahn SM, Oh JS et al (2022) Macrophage activation syndrome in rheumatic disease: clinical characteristics and prognosis of 20 adult patients. PLoS ONE 17(5):e267715. https:\/\/doi.org\/10.1371\/journal.pone.0267715","journal-title":"PLoS ONE"},{"issue":"2","key":"7465_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","volume":"82","author":"ME Dewane","year":"2020","unstructured":"Dewane ME, Waldman R, Lu J (2020) Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol 82(2):267\u2013281. https:\/\/doi.org\/10.1016\/j.jaad.2019.06.1309","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"7465_CR4","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jid.2023.09.288","volume":"144","author":"H Zhu","year":"2024","unstructured":"Zhu H, Luo H, Skaug B et al (2024) Fibroblast subpopulations in systemic sclerosis: functional implications of individual subpopulations and correlations with clinical features. J Invest Dermatol 144(6):1251\u20131261. https:\/\/doi.org\/10.1016\/j.jid.2023.09.288","journal-title":"J Invest Dermatol"},{"issue":"1","key":"7465_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10238-021-00728-6","volume":"22","author":"S Negrini","year":"2022","unstructured":"Negrini S, Emmi G, Greco M et al (2022) Sjogren\u2019s syndrome: a systemic autoimmune disease. Clin Exp Med 22(1):9\u201325. https:\/\/doi.org\/10.1007\/s10238-021-00728-6","journal-title":"Clin Exp Med"},{"issue":"2","key":"7465_CR6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"JI Henter","year":"2007","unstructured":"Henter JI, Horne A, Arico M et al (2007) Hlh-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48(2):124\u2013131. https:\/\/doi.org\/10.1002\/pbc.21039","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"7465_CR7","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/art.39332","volume":"68","author":"A Ravelli","year":"2016","unstructured":"Ravelli A, Minoia F, Dav\u00ec S et al (2016) 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation collaboration. Arthritis Rheumatol 68(3):566\u2013576. https:\/\/doi.org\/10.1002\/art.39332","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"7465_CR8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/ard-2022-223739","volume":"82","author":"F De Benedetti","year":"2023","unstructured":"De Benedetti F, Grom AA, Brogan PA et al (2023) Efficacy and safety of emapalumab in macrophage activation syndrome. Ann Rheum Dis 82(6):857\u2013865. https:\/\/doi.org\/10.1136\/ard-2022-223739","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"7465_CR9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1080\/03009742.2020.1729405","volume":"49","author":"M Honda","year":"2020","unstructured":"Honda M, Moriyama M, Kondo M, Kumakura S, Murakawa Y (2020) Tofacitinib-induced remission in refractory adult-onset Still\u2019s disease complicated by macrophage activation syndrome. Scand J Rheumatol 49(4):336\u2013338. https:\/\/doi.org\/10.1080\/03009742.2020.1729405","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"7465_CR10","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jbspin.2013.04.011","volume":"80","author":"C Banse","year":"2013","unstructured":"Banse C, Vittecoq O, Benhamou Y, Gauthier-Prieur M, Lequerre T, Levesque H (2013) Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still\u2019s disease. Joint Bone Spine 80(6):653\u2013655. https:\/\/doi.org\/10.1016\/j.jbspin.2013.04.011","journal-title":"Joint Bone Spine"},{"issue":"12","key":"7465_CR11","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1111\/imj.12002","volume":"42","author":"NK Loh","year":"2012","unstructured":"Loh NK, Lucas M, Fernandez S, Prentice D (2012) Successful treatment of macrophage activation syndrome complicating adult still disease with anakinra. Intern Med J 42(12):1358\u20131362. https:\/\/doi.org\/10.1111\/imj.12002","journal-title":"Intern Med J"},{"issue":"10315","key":"7465_CR12","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","volume":"398","author":"N Ruperto","year":"2021","unstructured":"Ruperto N, Brunner HI, Synoverska O et al (2021) Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet 398(10315):1984\u20131996. https:\/\/doi.org\/10.1016\/S0140-6736(21)01255-1","journal-title":"Lancet"},{"issue":"6","key":"7465_CR13","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/annrheumdis-2019-216699","volume":"79","author":"Q Hu","year":"2020","unstructured":"Hu Q, Wang M, Jia J et al (2020) Tofacitinib in refractory adult-onset still\u2019s disease: 14 cases from a single centre in china. Ann Rheum Dis 79(6):842\u2013844. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216699","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"7465_CR14","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1080\/1744666X.2017.1372194","volume":"13","author":"P Ruscitti","year":"2017","unstructured":"Ruscitti P, Cipriani P, Di Benedetto P et al (2017) Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? Expert Rev Clin Immunol 13(11):1041\u20131047. https:\/\/doi.org\/10.1080\/1744666X.2017.1372194","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"7465_CR15","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1007\/s10067-020-04949-0","volume":"39","author":"R Wang","year":"2020","unstructured":"Wang R, Li T, Ye S et al (2020) Macrophage activation syndrome associated with adult-onset Still\u2019s disease: a multicenter retrospective analysis. Clin Rheumatol 39(8):2379\u20132386. https:\/\/doi.org\/10.1007\/s10067-020-04949-0","journal-title":"Clin Rheumatol"},{"issue":"4","key":"7465_CR16","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1093\/rheumatology\/keac440","volume":"62","author":"L Gillard","year":"2023","unstructured":"Gillard L, Pouchot J, Cohen-Aubart F et al (2023) Jak inhibitors in difficult-to-treat adult-onset Still\u2019s disease and systemic-onset juvenile idiopathic arthritis. Rheumatology (Oxford) 62(4):1594\u20131604. https:\/\/doi.org\/10.1093\/rheumatology\/keac440","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"7465_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-med-061813-012806","volume":"66","author":"GS Schulert","year":"2015","unstructured":"Schulert GS, Grom AA (2015) Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies. Annu Rev Med 66(1):145\u2013159. https:\/\/doi.org\/10.1146\/annurev-med-061813-012806","journal-title":"Annu Rev Med"},{"issue":"4","key":"7465_CR18","doi-asserted-by":"publisher","first-page":"101515","DOI":"10.1016\/j.berh.2020.101515","volume":"34","author":"G Griffin","year":"2020","unstructured":"Griffin G, Shenoi S, Hughes GC (2020) Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy. Best Pract Res Clin Rheumatol 34(4):101515. https:\/\/doi.org\/10.1016\/j.berh.2020.101515","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"7465_CR19","doi-asserted-by":"publisher","unstructured":"He T, Xia Y, Luo Y, Yang J (2023) Jak inhibitors in systemic juvenile idiopathic arthritis. Front Pediatr 11. https:\/\/doi.org\/10.3389\/fped.2023.1134312","DOI":"10.3389\/fped.2023.1134312"},{"issue":"1","key":"7465_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00296-022-05231-z","volume":"43","author":"E Liquidano-Perez","year":"2023","unstructured":"Liquidano-Perez E, Maza-Ramos G, Salazar-Bail\u00f3n JL, Yamazaki-Nakashimada MA, Rivas-Larrauri F (2023) Therapeutic plasma exchange in refractory macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a case-based review. Rheumatol Int 43(1):183\u2013189. https:\/\/doi.org\/10.1007\/s00296-022-05231-z","journal-title":"Rheumatol Int"},{"issue":"1","key":"7465_CR21","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13075-018-1685-x","volume":"20","author":"MY Furuya","year":"2018","unstructured":"Furuya MY, Asano T, Sumichika Y et al (2018) Tofacitinib inhibits granulocyte-macrophage colony-stimulating factor-induced nlrp3 inflammasome activation in human neutrophils. Arthritis Res Ther 20(1):196. https:\/\/doi.org\/10.1186\/s13075-018-1685-x","journal-title":"Arthritis Res Ther"},{"key":"7465_CR22","doi-asserted-by":"publisher","unstructured":"Huang Z, Lee PY, Yao X, Zheng S, Li T (2019) Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis. Pediatrics 143(5). https:\/\/doi.org\/10.1542\/peds.2018-2845","DOI":"10.1542\/peds.2018-2845"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07465-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07465-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07465-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T09:20:45Z","timestamp":1749115245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07465-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["7465"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07465-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"15 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethics committee of Yantai Yuhuangding Hospital reviewed and approved the studies involving human participants. The patients\/participants provided their written informed consent to publish any potentially identifiable images or data presented in the article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}